Disclaimer: This is an early beta prototype. If you find any error, with data or functionality, please let us know via this page.

Conditions

Interventions

Lay summary

The purpose of this study is to investigate the effectiveness and safety of TMC435 compared with placebo in participants who are infected with genotype 1 hepatitis C virus who have never received treatment before. Participants will also receive peginterferon alfa-2a or peginterferon alfa-2b and ribavirin as part of their treatment.

Documents

Results

 

Publications

Registries